Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas increased his stake during 2025, adding 3,398,055 shares year-to-date, including 301,101 shares bought between Nov 19–28, 2025. Following these purchases, his total ownership stands at 6,459,985 shares. The company noted record-breaking Q3 2025 results across revenue, gross profit, and gross margins but said its valuation remains under pressure. The release directs investors to Form 4 filings for transaction-level details such as ownership form, dates, amounts, and prices.
Positive
- CEO purchased 3,398,055 shares year-to-date 2025
- Nov 19–28, 2025 purchases totaled 301,101 shares
- Total CEO ownership increased to 6,459,985 shares
- Company reported record-breaking Q3 2025 revenue and margins
Negative
- Company valuation remains under pressure despite record Q3 results
News Market Reaction – COSM
On the day this news was published, COSM declined 2.20%, reflecting a moderate negative market reaction. Argus tracked a trough of -16.4% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $471K from the company's valuation, bringing the market cap to $21M at that time. Trading volume was very high at 3.1x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
COSM was roughly flat at -0.02% while peers were mixed: gains in SNYR (+3.39%), EDAP (+2.17%), QIPT (+1.2%) versus declines in ZYXI and YI, indicating stock-specific dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Strategic partnership | Positive | -10.8% | Prime Ledger deal to manage $300M treasury and tokenize IP assets. |
| Dec 02 | Insider share purchases | Positive | -2.2% | CEO increased ownership to 6,459,985 shares after 2025 acquisitions. |
| Nov 17 | Earnings update | Positive | -3.1% | Record Q3 2025 with strong revenue, gross profit and margin gains. |
| Oct 31 | R&D program launch | Positive | -10.0% | New nanotechnology R&D program for enhanced nutraceutical formulas. |
| Oct 21 | Crypto asset purchase | Positive | +1.0% | Additional $200,000 Ethereum purchase under $300M digital assets facility. |
Recent news has generally been positive but followed by negative price reactions, suggesting a pattern of selling or skepticism on good news.
Over the last few months, Cosmos Health issued several positive updates, including record Q3 2025 results with higher revenue, gross profit and margins on Nov 17, 2025, plus multiple Ethereum purchases under a $300M digital assets facility. It also launched a nanotechnology R&D program and, on Dec 3, 2025, announced a strategic partnership to manage a $300M treasury and tokenize IP. Despite this, most of these releases saw negative next‑day moves, framing today’s insider buying against a backdrop of market caution.
Regulatory & Risk Context
An effective Form S-3 shelf registering up to $200,000,000 of securities plus an ATM program of up to $100,000,000 of common stock gives the company significant issuance capacity, with stated uses including crypto asset acquisitions, general corporate purposes and working capital.
Market Pulse Summary
This announcement highlights substantial insider accumulation, with the CEO adding over 3.3M shares in 2025 and citing record Q3 performance across revenue, gross profit and margins. Context from recent filings shows a $200,000,000 S-3 shelf and a large ATM program aimed partly at crypto asset acquisitions. Investors may track future Form 4 filings, usage of the shelf and ATM, and follow‑through on growth and digital‑asset strategies as key indicators.
Key Terms
form 4 regulatory
AI-generated analysis. Not financial advice.
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Chief Executive Officer Greg Siokas has further increased his ownership in the Company through continued share acquisitions during November 2025.
Specifically, between 19 November and 28 November 2025, Mr. Siokas executed five transactions, acquiring 301,101 shares.
So far in 2025, he has added 3,398,055 shares to his holdings.
Following these acquisitions, his total ownership has increased to 6,459,985 shares of Cosmos Health.
Greg Siokas, CEO of Cosmos Health, stated: “We recently reported record-breaking Q3 2025 results, and I expect this strong momentum to continue into Q4. Despite our all-time-high achievements in quarterly revenue, gross profit and gross margins, driven by robust growth across all core business segments, our valuation remains under pressure.
I have increased my ownership by well over three million shares since the beginning of the year because I firmly believe Cosmos is well positioned to deliver significant value. I remain committed to supporting the Company in every way necessary so that we can achieve our objectives as we expand globally and advance our pipeline of innovative products.”
Information on Mr. Siokas’s Recent Transactions:
Please refer to the filings on Form 4 filed with the SEC and available on the SEC's website for more information about the nature of the transactions, including details such as “Ownership Form”, “Transaction Date”, “Amount”, “Price”, and other relevant information regarding the shares acquired by Mr. Siokas.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
FAQ
How many Cosmos Health (COSM) shares did CEO Greg Siokas buy in 2025?
What were the dates and size of Greg Siokas's November 2025 purchases of COSM?
What is Greg Siokas's total Cosmos Health (COSM) ownership after the November buys?
Do the Cosmos Health disclosures include transaction prices and detailed filing info for COSM insider buys?
Does Greg Siokas's buying reflect company performance for COSM in 2025?
